Payment overview · 2025
General Payments
$711.67
42 reported records · 15 companies
Healthcare provider profile · identity verified
Peter O Kuponiyi, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Addiction Medicine · EGG HARBOR TOWNSHIP, NJ · NPI 1285674010
Verified facts
What the public records show
CMS Open Payments records show Peter O Kuponiyi, MD received $711.67 in general payments during 2025 across 42 reported records.
Amgen Inc. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 586 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 405 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $139.67 | 19.6% | 9 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $104.86 | 14.7% | 6 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $71.39 | 10.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.83 | 9.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.77 | 8.7% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $50.02 | 7.0% | 3 | 2025 |
| Bavarian Nordic A/S | Unresolved — no canonical attribution shown | $37.16 | 5.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.22 | 5.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.87 | 4.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.10 | 3.7% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.91 | 2.9% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.78 | 2.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.17 | 2.5% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.22 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.70 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $711.67 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $104.86 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $78.27 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $78.27 | 5 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $71.39 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.77 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.77 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $50.02 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $42.65 | 3 | 2025 |
Source payment records
|
|||||
| Vivotif Normalized: vivotif |
Drug | Bavarian Nordic A/S | $37.16 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.28 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.55 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.87 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $26.10 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA Normalized: invega |
Drug | Janssen Pharmaceuticals, Inc | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.17 | 2 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 44 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
75 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | 25 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
586 | 585 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
405 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 3922 | 3908 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 3385 | 2432 |
| Amlodipine Besylate | Amlodipine Besylate | 1339 | 276 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1109 | 289 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 1025 | 1022 |
| Gabapentin | Gabapentin | 933 | 151 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 586 | 585 |
| Lisinopril | Lisinopril | 583 | 117 |
| Omeprazole | Omeprazole | 562 | 158 |
| Levothyroxine Sodium | Levothyroxine Sodium | 556 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 552 | 105 |
| Alprazolam | Alprazolam | 494 | 77 |
| Potassium Chloride | Potassium Chloride | 468 | 104 |
| Furosemide | Furosemide | 455 | 116 |
| Metformin Hcl | Metformin Hcl | 426 | 118 |
| Carvedilol | Carvedilol | 413 | 70 |
| Eliquis | Apixaban | 405 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 378 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 345 | 107 |
| Metoprolol Tartrate | Metoprolol Tartrate | 337 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 288 | 46 |
| Clonazepam | Clonazepam | 285 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 275 | 51 |
| Tramadol Hcl | Tramadol Hcl | 272 | 89 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 261 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 260 | 71 |
| Losartan Potassium | Losartan Potassium | 260 | 71 |
| Mirtazapine | Mirtazapine | 256 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 75 |
| Pravastatin Sodium | Pravastatin Sodium | 239 | 49 |
| Meloxicam | Meloxicam | 227 | 80 |
| Montelukast Sodium | Montelukast Sodium | 225 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 223 | 102 |
| Glimepiride | Glimepiride | 207 | 61 |
| Azithromycin | Azithromycin | 203 | 150 |
| Donepezil Hcl | Donepezil Hcl | 202 | 39 |
| Sertraline Hcl | Sertraline Hcl | 189 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 189 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 187 | 44 |
| Divalproex Sodium | Divalproex Sodium | 187 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 53 |
| Famotidine | Famotidine | 182 | 31 |
| Warfarin Sodium | Warfarin Sodium | 181 | 14 |
| Levetiracetam | Levetiracetam | 171 | 32 |
| Simvastatin | Simvastatin | 168 | 49 |
| Spironolactone | Spironolactone | 168 | 33 |
| Ibuprofen | Ibuprofen | 167 | 57 |
| Irbesartan | Irbesartan | 164 | 30 |
| Repaglinide | Repaglinide | 161 | 19 |
| Sucralfate | Sucralfate | 156 | suppressed |
| Jardiance | Empagliflozin | 149 | 28 |
| Clonidine Hcl | Clonidine Hcl | 148 | 39 |
| Trazodone Hcl | Trazodone Hcl | 145 | 29 |
| Alendronate Sodium | Alendronate Sodium | 142 | 46 |
| Allopurinol | Allopurinol | 142 | 38 |
| Ezetimibe | Ezetimibe | 133 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 133 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 128 | 42 |
| Twinrix | Hepatitis A And B Vaccine/Pf | 123 | 69 |
| Methylprednisolone | Methylprednisolone | 122 | 86 |
| Buspirone Hcl | Buspirone Hcl | 118 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 116 | 25 |
| Labetalol Hcl | Labetalol Hcl | 115 | 20 |
| Colchicine | Colchicine | 114 | 20 |
| Ozempic | Semaglutide | 114 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 28 |
| Celecoxib | Celecoxib | 106 | 41 |
| Finasteride | Finasteride | 105 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 105 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 101 | 24 |
| Valsartan | Valsartan | 99 | 19 |
| Amoxicillin | Amoxicillin | 98 | 77 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 98 | 58 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 97 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 97 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 52 |
| Bumetanide | Bumetanide | 89 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 29 |
| Temazepam | Temazepam | 89 | 31 |
| Midodrine Hcl | Midodrine Hcl | 83 | 14 |
| Naproxen | Naproxen | 83 | 35 |
| Farxiga | Dapagliflozin Propanediol | 80 | 25 |
| Prednisone | Prednisone | 79 | 26 |
| Topiramate | Topiramate | 77 | 23 |
| Ondansetron Odt | Ondansetron | 76 | 22 |
| Linzess | Linaclotide | 75 | 26 |
| Chlorthalidone | Chlorthalidone | 73 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 73 | 43 |
| Atenolol | Atenolol | 72 | 19 |
| Baclofen | Baclofen | 72 | 13 |
| Ranolazine Er | Ranolazine | 72 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 72 | 62 |
| Januvia | Sitagliptin Phosphate | 68 | 16 |
| Ramipril | Ramipril | 67 | 18 |
| Risperidone | Risperidone | 67 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 65 | 15 |
| Lorazepam | Lorazepam | 65 | 20 |
| Memantine Hcl | Memantine Hcl | 65 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 65 | 23 |
| Havrix | Hepatitis A Virus Vaccine/Pf | 63 | 52 |
| Typhim Vi | Typhoid Vi Polysacch Vaccine | 63 | 63 |
| Lansoprazole | Lansoprazole | 62 | suppressed |
| Levemir Flexpen | Insulin Detemir | 62 | 17 |
| Lidocaine | Lidocaine | 62 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 41 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 57 | 57 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 57 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 25 |
| Torsemide | Torsemide | 57 | 12 |
| Pregabalin | Pregabalin | 56 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 55 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 54 | 17 |
| Mupirocin | Mupirocin | 54 | 33 |
| Ammonium Lactate | Ammonium Lactate | 52 | 29 |
| Nystatin | Nystatin | 52 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 33 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | 20 |
| Trulicity | Dulaglutide | 50 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 49 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 48 | 14 |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 46 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 46 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 46 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | suppressed |
| Latanoprost | Latanoprost | 45 | 18 |
| Rybelsus | Semaglutide | 44 | 12 |
| Fluconazole | Fluconazole | 42 | 25 |
| Glipizide | Glipizide | 42 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 42 | 16 |
| Ketoconazole | Ketoconazole | 41 | 17 |
| Brimonidine Tartrate | Brimonidine Tartrate | 40 | suppressed |
| Lactulose | Lactulose | 40 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 38 | suppressed |
| Ipol | Poliomyelitis Vaccine, Killed | 37 | 37 |
| Azelastine Hcl | Azelastine Hcl | 36 | 21 |
| Calcium Acetate | Calcium Acetate | 36 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 36 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 23 |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 17 |
| Meclizine Hcl | Meclizine Hcl | 31 | 15 |
| Diazepam | Diazepam | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Brilinta | Ticagrelor | 29 | suppressed |
| Gemtesa | Vibegron | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Humalog | Insulin Lispro | 26 | suppressed |
| Loperamide | Loperamide Hcl | 26 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Insulin Lispro | Insulin Lispro | 25 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 25 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Clotrimazole | Clotrimazole | 24 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 13 |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 21 | suppressed |
| Nystop | Nystatin | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 12 |
| Desloratadine | Desloratadine | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 13 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 16 |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 16 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 15 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Darunavir | Darunavir | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Menquadfi | Mening Vac A,c,y,w135,c-Tet/Pf | 13 | 13 |
| Minoxidil | Minoxidil | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | 13 |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Adderall | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Budesonide | Budesonide | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Ritonavir | Ritonavir | 12 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 12 | suppressed |
| Tivicay | Dolutegravir Sodium | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Maraviroc | Maraviroc | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $711.67 · 42 records | Amgen Inc. | AIRSUPRA, AUSTEDO XR, BREZTRI, CAPLYTA, EVENITY, HORIZANT, INVEGA, KRYSTEXXA, Kerendia, NURTEC ODT, OTEZLA, Omnipod, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Vivotif, ZAVZPRET | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error